Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-16

Study Completion Date

2021-11-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 2 study of the drug ketamine for the treatment of depression in cancer patients receiving palliative care. The purpose of this study is to see how useful the drug is at decreasing the severity of depression these patients. Ketamine will be given through the nose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer

NCT02836288

Cancer Depression

COMPLETED EARLY_PHASE1

Effect of Ketamine on Fatigue Following Cancer Therapy

NCT02317341

Cancer Fatigue Ketamine

TERMINATED EARLY_PHASE1

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

NCT01680172

Cancer Depression Anxiety

TERMINATED PHASE2

Polyglutamate Camptothecin in Treating Patients With Advanced Cancer

NCT00059917

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Transdermal Methylphenidate for Cancer-Related Fatigue

NCT01124500

Head and Neck Cancer

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Cancer Palliative Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketamine

Three doses of ketamine will be given intranasal:

* Dose 1 will be 50 mg on Day 1
* Dose 2 will be between 50-100 mg on Day 4
* Dose 3 will be between 50-150 mg on Day 7

Group Type EXPERIMENTAL

Ketamine Hydrochloride

Intervention Type DRUG

Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine Hydrochloride

Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide written, voluntary informed consent prior to study enrollment. Participants must be capable of consenting to treatment as substitute decision makers will not be allowed to consent to the study on their behalf
* Males and females ≥ 18 years of age
* Patient is receiving palliative care at Princess Margaret Cancer Centre (PM) including all in-patient units and outpatients
* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for Major Depressive Disorder (MDD), with a current Major Depressive Episode (MDE)
* Depression severity must be in the moderate to severe range, as determined by a Montgomery-Åsberg Depression Rating Scale (MADRS) score greater than or equal to 20
* Participants must have a confirmed diagnosis of cancer and an estimated life expectancy of less than twelve months, as determined by the palliative care physician

Exclusion Criteria

* Presence of delirium or suspected delirium
* Severe hypertension or severe cardiac decompensation
* Previous stroke history
* History of intolerability, hypersensitivity or allergy to ketamine
* Patients with bipolar disorder, psychotic disorders, substance use disorders or active suicidality based on a Mini-International Neuropsychiatric Interview (MINI) conducted by a delegated physician will also be excluded
* Current symptoms of psychosis or perceptual disturbances of any kind per investigator discretion
* Pregnancy or breastfeeding women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No